AI-focused Notable Labs score $40M in funding; Seattle Genetics/Astellas submit marketing application for enfortumab vedotin
→ The AI experts at Notable Labs have garnered another $40 million to scale their automated laboratory and analytics platform. Designed to match patients to clinical trials by predicting quickly who are most likely to respond to a cancer drug, the startup has pitched itself as an advocate for patients and facilitator to pharma companies. With the Series B cash, Notable Labs plans to expand their platform both in terms of geography — building labs outside of North America — and cancer types (it’s currently focused on hematological cancers).
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.